Contributions
Abstract: P1868
Type: Poster
Abstract Category: Late breaking news
Objective: To determine the association between cerebrospinal fluid (CSF) oligoclonal bands (OCB) status in multiple sclerosis (MS) and risk of reaching EDSS (Expanded disability status scale) milestones:3, 4, 6 and conversion to secondary progressive (SP) MS.
Background: MS patients without the MS typical OCB distribution of immunoglobulin gamma (IgG) - OCB negative (OCB-) in the CSF have a different genetic background than MS patients with an OCB+ pattern. OCB- patients as a group are significantly different than OCB+ patients in terms of brain lesion distribution and signs of global and regional atrophy.
Design/methods: We used data from clinically definite MS patients with known OCB status in the Swedish MS register. Date of birth, MS onset and date at sustained EDSS score milestones 3, 4, 6, date at conversion to SPMS, sex, and duration of exposure to first- and second-line Immunomodulatory treatments (IMTs) was collected. Multivariate Cox regression models were used to investigate the influence of OCB-status on the risk of reaching clinical milestones.
Results: After controlling for sex, chronological age, age at the onset of MS, calendar year of CSF examination and exposure to IMTs (as time varying covariate), OCB positivity was associated with 23% (95%CI: 1.03 to 1.47, P=0.02, n=5704) increased risk of conversion to SPMS, 33% (95%CI: 1.15 to 1.54, P< 0.001, n=4725) increased risk of reaching EDSS score 3, 38% (95%CI: 1.16 to 1.64, P< 0.001, n=5445) increased risk of reaching EDSS score 4 and, 23% (95%CI: 1.00 to 1.45, P=0.047, n=6030) increased risk of reaching EDSS score 6.
Conclusions: OCB carriership in CSF confers unfavourable MS outcomes: both higher risk to reach EDSS milestones and higher risk to convert to secondary progressive phase. The effect was much stronger in the short-term than long-term outcomes suggesting higher disease modifying effect of OCB presence in early stage of MS.
Disclosure: This study was supported by Biogen.
Ali Mnouchehrinia and Virginija Karrenbauer has no conflict of interest.
an Hillert received honoraria for serving on advisory boards for Biogen, Sanofi-Genzyme and Novartis and speaker's fees from Biogen, Merck-Serono, Bayer-Schering, Teva and Sanofi-Genzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis, Sanofi-Genzyme and Bayer-Schering.
Abstract: P1868
Type: Poster
Abstract Category: Late breaking news
Objective: To determine the association between cerebrospinal fluid (CSF) oligoclonal bands (OCB) status in multiple sclerosis (MS) and risk of reaching EDSS (Expanded disability status scale) milestones:3, 4, 6 and conversion to secondary progressive (SP) MS.
Background: MS patients without the MS typical OCB distribution of immunoglobulin gamma (IgG) - OCB negative (OCB-) in the CSF have a different genetic background than MS patients with an OCB+ pattern. OCB- patients as a group are significantly different than OCB+ patients in terms of brain lesion distribution and signs of global and regional atrophy.
Design/methods: We used data from clinically definite MS patients with known OCB status in the Swedish MS register. Date of birth, MS onset and date at sustained EDSS score milestones 3, 4, 6, date at conversion to SPMS, sex, and duration of exposure to first- and second-line Immunomodulatory treatments (IMTs) was collected. Multivariate Cox regression models were used to investigate the influence of OCB-status on the risk of reaching clinical milestones.
Results: After controlling for sex, chronological age, age at the onset of MS, calendar year of CSF examination and exposure to IMTs (as time varying covariate), OCB positivity was associated with 23% (95%CI: 1.03 to 1.47, P=0.02, n=5704) increased risk of conversion to SPMS, 33% (95%CI: 1.15 to 1.54, P< 0.001, n=4725) increased risk of reaching EDSS score 3, 38% (95%CI: 1.16 to 1.64, P< 0.001, n=5445) increased risk of reaching EDSS score 4 and, 23% (95%CI: 1.00 to 1.45, P=0.047, n=6030) increased risk of reaching EDSS score 6.
Conclusions: OCB carriership in CSF confers unfavourable MS outcomes: both higher risk to reach EDSS milestones and higher risk to convert to secondary progressive phase. The effect was much stronger in the short-term than long-term outcomes suggesting higher disease modifying effect of OCB presence in early stage of MS.
Disclosure: This study was supported by Biogen.
Ali Mnouchehrinia and Virginija Karrenbauer has no conflict of interest.
an Hillert received honoraria for serving on advisory boards for Biogen, Sanofi-Genzyme and Novartis and speaker's fees from Biogen, Merck-Serono, Bayer-Schering, Teva and Sanofi-Genzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis, Sanofi-Genzyme and Bayer-Schering.